The prime objective of the Boston University Alzheimer's Disease Center (BU ADC) is to provide resources to support high impact studies on the pathogenesis, detection, and treatment of Alzheimer's Disease (AD) and related disorders. The leadership team and investigators affiliated with the BU ADC represent a dynamic forward thinking team of clinicians and scientists who have made significant contributions to AD-related research and are committed to advancing the field in the years ahead. The BU ADC consists of an Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Education and Information Transfer Core, and a Translational and Transgenic Core. The BU ADC has four aims.
Aim 1 is to foster and support high-impact, innovative, state of the art research on brain aging and AD by: a) identifying, recruiting, and thoroughly characterizing subjects willing to participate in clinical trials and other cutting-edge clinical research studies;b) collecting, storing, analyzing, and distribute biological samples to support high priority AD-related research;c) conducting state-of the-art diagnostic neuropathological evaluation and maximize CNS tissue donation to support state of the art tissue-based research;and d) fostering innovative AD research through a strong pilot project program.
Aim 2 is to collect and submit high quality data to the Data Management and Statistics Core for timely UDS submissions to the NACC database and for data sharing with qualified AD investigators engaged in cutting edge AD-related research while ensuring data security and integrity.
Aim 3 is to support and inform the communities we serve regarding the benefits of the BU ADC and AD research and to provide a high-quality training environment for professionals at all career levels. The BU ADC has developed innovative approaches to educate medical students about AD and has pioneered methods to increase African American brain donation.
Aim 4 is to breed and disseminate transgenic mouse models of AD and related disorders and to provide specialized technical services to support cutting edge translational AD-related research.
Alzheimer's disease (AD) affects over 5 million people and is the 7th leading cause of death in the USA. Despite advances in understanding of how AD and other age-related diseases cause loss of brain function, much more research is needed on how AD and related disorders develop, how to detect them at their earliest stages, and how to treat them effectively once they develop. The mission of the Boston University Alzheimer's Disease Center is to provide resources to accelerate research addressing these vital questions.
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823|
|Li, Jinlei; Ogrodnik, Matthew; Devine, Sherral et al. (2018) Practical risk score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study. Alzheimers Dement 14:35-42|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
|Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360|
|Cherry, Jonathan D; Mez, Jesse; Crary, John F et al. (2018) Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun 6:115|
|Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
Showing the most recent 10 out of 791 publications